Challenges and responses in human vaccine development

Current Opinion in Immunology

Volumn 28, Issue 1, 2014, Pages 18-26

  Kaufmann, Stefan HE ^a   Juliana McElrath, M ^b   Lewis, David JM ^c   Del Giudice, Giuseppe ^d  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MALARIA VACCINE; VACCINE;

CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MALARIA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; VACCINES;

EID: 84896257134     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.01.009     Document Type: Review

References (72)

1. Kaufmann S.H.E. The New Plagues: Pandemics and Poverty in a Globalized World 2009, Haus Publishing, London.
2. Pollard A.J., Savulescu J., Oxford J., Hill A.V., Levine M.M., Lewis D.J., Read R.C., Graham D.Y., Sun W., Openshaw P., et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis 2012, 12:903-905.
3. Rappuoli R., Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473:463-469.
4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
5. Holst J., Oster P., Arnold R., Tatley M.V., Naess L.M., Aaberge I.S., Galloway Y., McNicholas A., O'Hallahan J., Rosenqvist E., et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 2013, 9:1241-1253.
6. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., Dull P., Kimura A. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
7. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., Caugant D.A., Kriz P., Abad R., Bambini S., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13:416-425.
8. European Medicines Agency Bexsero: meningococcal group B vaccine (rDNA, component, adsorbed). EMA/755874/2012 2013, http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002333/human_med_001614.jsp%26mid=WC0b01ac058001d124.
9. Seib K.L., Zhao X., Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect 2012, 18(Suppl 5):109-116.
10. Donati C., Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Ann N Y Acad Sci 2013, 1285:115-132.
11. Muzzi A., Mora M., Pizza M., Rappuoli R., Donati C. Conservation of meningococcal antigens in the genus Neisseria. MBio 2013, 4:e00163-e213.
12. Scarselli M., Arico B., Brunelli B., Savino S., Di M.F., Palumbo E., Veggi D., Ciucchi L., Cartocci E., Bottomley M.J., et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 2011, 3:91ra62.
13. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342:592-598.
14. Lyumkis D., Julien J.P., de V.N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 10.1126/science.1245627.
15. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 10.1126/science.1245625.
16. Szarewski A. Cervarix(R): a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev Vaccines 2012, 11:645-657.
17. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013, 12:13-30.
18. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012, 11:349-366.
19. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., Rock M.T., Edwards K.M., Del G.G., Rappuoli R., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2:15ra5.
20. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., Baehner F., Borkowski A., Tsai T.F., Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
21. Mannino S., Villa M., Apolone G., Weiss N.S., Groth N., Aquino I., Boldori L., Caramaschi F., Gattinoni A., Malchiodi G., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012, 176:527-533.
22. Van Buynder P.G., Konrad S., Van Buynder J.L., Brodkin E., Krajden M., Ramler G., Bigham M. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013, 31:6122-6128.
23. Centers for Disease Control Updated CDC estimates of 2009 H1N1 influenza cass, hospitalizations and deaths in the United States, April 2009-April 2010 2014, http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
24. Gibson D.G., Smith H.O., Hutchison C.A., Venter J.C., Merryman C. Chemical synthesis of the mouse mitochondrial genome. Nat Methods 2010, 7:901-903.
25. Dormitzer P.R., Suphaphiphat P., Gibson D.G., Wentworth D.E., Stockwell T.B., Algire M.A., Alperovich N., Barro M., Brown D.M., Craig S., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013, 5:185ra68.
26. Gray G.E., Allen M., Moodie Z., Churchyard G., Bekker L.G., Nchabeleng M., Mlisana K., Metch B., de B.G., Latka M.H., et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011, 11:507-515.
27. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., Shea J.E., McClain J.B., Hussey G.D., Hanekom W.A., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
28. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., Jiwariyavej V., Dulyachai W., Pengsaa K., Wartel T.A., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
29. Zak D.E., Andersen-Nissen E., Peterson E.R., Sato A., Hamilton M.K., Borgerding J., Krishnamurty A.T., Chang J.T., Adams D.J., Hensley T.R., et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A 2012, 109:E3503-E3512.
30. Furman D., Jojic V., Kidd B., Shen-Orr S., Price J., Jarrell J., Tse T., Huang H., Lund P., Maecker H.T., et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013, 9:659.
31. Franco L.M., Bucasas K.L., Wells J.M., Nino D., Wang X., Zapata G.E., Arden N., Renwick A., Yu P., Quarles J.M., et al. Integrative genomic analysis of the human immune response to influenza vaccination. Elife 2013, 2:e00299.
32. Tan Y., Tamayo P., Nakaya H., Pulendran B., Mesirov J.P., Haining W.N. Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. Eur. J Immunol 2013, 10.1002/eji.201343657.
33. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., Pirani A., Gernert K., Deng J., Marzolf B., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
34. Mastelic B., Lewis D.J., Golding H., Gust I., Sheets R., Lambert P.H. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety. Biologicals 2013, 41:115-124.
35. Liquet B., Le Cao K.A., Hocini H., Thiebaut R. A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinform 2012, 13:325.
36. Obermoser G., Presnell S., Domico K., Xu H., Wang Y., Anguiano E., Thompson-Snipes L., Ranganathan R., Zeitner B., Bjork A., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38:831-844.
37. Wang I.M., Bett A.J., Cristescu R., Loboda A., ter M.J. Transcriptional profiling of vaccine-induced immune responses in humans and non-human primates. Microb Biotechnol 2012, 5:177-187.
38. Chaussabel D., Quinn C., Shen J., Patel P., Glaser C., Baldwin N., Stichweh D., Blankenship D., Li L., Munagala I., et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008, 29:150-164.
39. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., Richards D.R., McDonald-Smith G.P., Gao H., Hennessy L., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
40. Maraskovsky E., Rockman S., Dyson A., Koernig S., Becher D., Morelli A.B., Barnden M., Camuglia S., Bodle J., Vandenberg K., et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine 2012, 30:7400-7406.
41. UNAIDS, WHO Global Report: UNAIDS Report on the Global AIDS Epidemic 2013 2013, WHO, Geneva.
42. Haynes B.F., McElrath M.J. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013, 8:326-332.
43. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
44. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
45. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van G.F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
46. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del R.C., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
47. Hammer S.M., Sobieszczyk M.E., Janes H., Karuna S.T., Mulligan M.J., Grove D., Koblin B.A., Buchbinder S.P., Keefer M.C., Tomaras G.D., et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013, 369:2083-2092.
48. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de S.M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
49. Frahm N., DeCamp A.C., Friedrich D.P., Carter D.K., Defawe O.D., Kublin J.G., Casimiro D.R., Duerr A., Robertson M.N., Buchbinder S.P., et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012, 122:359-367.
50. Curlin M.E., Huang M.L., Lu X., Celum C.L., Sanchez J., Selke S., Baeten J.M., Zuckerman R.A., Erdman D.D., Corey L. Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men. PLoS ONE 2010, 5:e11321.
51. Ottenhoff T.H.M., Kaufmann S.H.E. Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog 2012, 8:e1002607.
52. Frick M. The TB Vaccines Pipeline: Where are we going, where have we been?. 2013 Pipeline Report 2013, 263-283. HIV i-Base and Treatment Action Group, London.
53. Kaufmann S.H. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol 2012, 33:373-379.
54. Kaufmann S.H. Tuberculosis vaccines: time to think about the next generation. Semin Immunol 2013, 25:172-181.
55. Grode L., Ganoza C.A., Brohm C., Weiner J3, Eisele B., Kaufmann S.H.E. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clnical trial. Vaccine 2013, 31:1340-1348.
56. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., Tingskov P.N., Lingnau K., Nouta J., Hoff S.T., et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
57. Leroux-Roels I., Forgus S., De B.F., Clement F., Demoitie M.A., Mettens P., Moris P., Ledent E., Leroux-Roels G., Ofori-Anyinam O. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013, 31:2196-2206.
58. Spertini F., Audran R., Lurati F., Ofori-Anyinam O., Zysset F., Vandepapeliere P., Moris P., Demoitie M.A., Mettens P., Vinals C., et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb.) 2013, 93:179-188.
59. Montoya J., Solon J.A., Cunanan S.R., Acosta L., Bollaerts A., Moris P., Janssens M., Jongert E., Demoitie M.A., Mettens P., et al. A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013, 10.1007/s10875-013-9949-3.
60. Day C.L., Tameris M., Mansoor N., van R.M., de K.M., Geldenhuys H., Erasmus M., Makhethe L., Hughes E.J., Gelderbloem S., et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013, 188:492-502.
61. Smaill F., Jeyanathan M., Smieja M., Medina M.F., Thanthrige-Don N., Zganiacz A., Yin C., Heriazon A., Damjanovic D., Puri L., et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013, 5:205ra134.
62. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., Mauff K., Moyo S., Brittain N., Lawrie A., et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769-778.
63. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
64. Kagina B.M., Abel B., Scriba T.J., Hughes E.J., Keyser A., Soares A., Gamieldien H., Sidibana M., Hatherill M., Gelderbloem S., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
65. Mahomed H., Ehrlich R., Hawkridge T., Hatherill M., Geiter L., Kafaar F., Abrahams D.A., Mulenga H., Tameris M., Geldenhuys H., et al. Screening for TB in high school adolescents in a high burden setting in South Africa. Tuberculosis (Edinb.) 2013, 93:357-362.
66. Mahomed H., Ehrlich R., Hawkridge T., Hatherill M., Geiter L., Kafaar F., Abrahams D.A., Mulenga H., Tameris M., Geldenhuys H., et al. TB incidence in an adolescent cohort in South Africa. PLoS ONE 2013, 8:e59652.
67. World Health Organization World Malaria Report 2012 2012, WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/world_malaria_report_2012/en/.
68. Regules J.A., Cummings J.F., Ockenhouse C.F. The RTS S vaccine candidate for malaria. Expert Rev Vaccines 2011, 10:589-599.
69. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G., Doucka Y., Flamen A., Mordmuller B., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
70. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., Kabwende A.L., Adegnika A.A., Mordmuller B., Issifou S., Kremsner P.G., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295.
71. Olotu A., Fegan G., Wambua J., Nyangweso G., Awuondo K.O., Leach A., Lievens M., Leboulleux D., Njuguna P., Peshu N., et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120.
72. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., Holman L.A., James E.R., Billingsley P.F., Gunasekera A., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.